Cat. No.: DAA-001059
Product Information | |
---|---|
Product Name | Annexin V-FITC Early Apoptosis Detection Kit |
Description | The Annexin V-FITC Early Apoptosis Detection Kit enables researchers to identify early apoptotic cells within a cell population. Annexin V-FITC conjugated protein binds to cell surfaces expressing phosphatidylserine, an early apotosis marker. Cells stained with propidium iodide (PI), a non-cell-permeable DNA dye, indicate necrotic cells. Cells stained with both PI and annexin V-FITC demonstrate later stage apoptosis and early necrosis. This kit provides enough reagent to perform 100 assays, based on a 250 μl assay volume. |
Component | Annexin V-FITC Conjugate; 10X Annexin V Binding Buffer; Propidium Iodide (PI) Solution |
Target Information | |
---|---|
Target Name | ANXA5 |
UniProt No. | P08758 |
Gene ID | 308 |
Target Description | Annexin V belongs to the annexin family of proteins consisting of over 160 members. All annexin family members share the same charactersistic of Ca2+-dependent binding to negatively charged phospholipid surfaces. During early apoptosis, phosphatidylserine (PS) is translocated from the cytosolic side of the plasma membrane to the cellular surface. This translocation exposes PS to the extracellular environment with the plasma membrane left intact. Annexin V protein demonstrates high affinity, specificity, and sensitivity for PS and can be used as a marker of early apoptosis. In order to rule out "leaky" necrotic cells, annexin V must be used in tandem with reagents that determine the integrity of the cell membrane, such as propidium iodide. |
Alternative Names | Anchorin CII; Annexin V; Annexin-5; Calphobindin I (CPB-I); Endonexin II; Lipocortin V; Placental anticoagulant protein 4 (PP4); Placental anticoagulant protein I (PAP-I); Thromboplastin inhibitor; Vascular anticoagulant-alpha (VAC-alpha) |
Shipping & Storage | |
---|---|
Sipping | Shipping on dry ice. |
Storage | Store at -20°C. Please refer to protocols. |
Ace Therapeutics has a team of experts in the field of endocrine and metabolic research, aiming to provide innovative preclinical contract research solutions to cope with diabetes and its complications. We provide customized solutions and technical support, enabling the transformation of promising concepts into innovative treatments, thus accelerating the drug development process of diabetes.